Diabetic Foot Ulcer Treatment Market Outlook 2031
The Diabetic Foot Ulcer Treatment Market size was USD 4.40 Billion in 2022 and is likely to reach USD 7.06 Billion by 2031, expanding at a CAGR of 5.4% during 2023–2031. The growth of the market is attributed to the growing geriatric population across the globe and increasing prevalence of diabetes.
Diabetic foot ulcer (DFU) is major problems of diabetes mellitus. Major characteristic of diabetic foot are formed by diabetes mellitus. Therapeutic of wounds is normally an innate mechanism. But, wound healing process get delayed due to some metabolic disorders such as diabetes mellitus. DFU are majorly caused due to nerve damage, high blood sugar (hyperglycemia), irritated or wounded feet, and poor circulation. The primary symptoms of foot ulcer are redness, stenches, unusual swelling, and irritation.
Diabetic foot ulcer treatment includes wound dressings, control of blood sugar, negative pressure therapy, and removal of dead tissues. Hyperbaric oxygen therapy is one more DFU treatment but it is costly and in few cases, surgery improves results. Diabetic foot ulcers occur in around 15% of people who are suffering from diabetes and it is accountable for more than 81% of all diabetes-related lower-leg amputations.
Costly treatment of ulcers is hampering the utmost potential of the market. Many emerging countries are lacking in healthcare facilities. Adoption of new therapeutics, prioritization to avoid surgeries and amputations, and improved biologics are projected to aid the market expansion. Therefore, they offers substantial opportunities to generate revenue in the market.
Diabetic Foot Ulcer Treatment Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of diabetes and increasing incidence of diabetic foot ulcers are major factor responsible for the market growth over the forecast period.
- Rising awareness about treatment on disorders among people and rising demand of appropriate medications are projected to fuel the market growth.
- Increasing R&D in non-invasive approaches for the DHU treatment and rising consumption of alcohol and tobacco are expected to propel the growth of the market.
- Growing geriatric population across the globe, ongoing clinical trials, and advancements in research are anticipated to boost the market expansion in coming years.
- Accessibility to explicit dressings for particular type of foot ulcers is estimated to drive the expansion of the market.
- High cost of diabetic foot ulcer medication and care is expected to hamper the market growth in the coming years.
- Lack of awareness about specific treatment options, particularly in developing countries is projected to impede the market growth during the forecast period.
Scope of The Diabetic Foot Ulcer Treatment Market Report
The report on the global diabetic foot ulcer treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Diabetic Foot Ulcer Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Treatments (Biologics [Growth Factors and Skin Grafts], Wound Care Dressings [Alginate Dressings, Hydrofiber Dressings, Foam Dressings, Film Dressing, Hydrocolloid Dressings, Surgical Dressings, and Hydrogel Dressings], Therapy Devices [Negative Pressure Wound Therapy and Ultrasound Therapy], Antibiotic Medications, and Others), Ulcer Types (Ischemic Ulcer, Neuro-Ischemic Ulcer, and Neuropathic Ulcer)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH
Diabetic Foot Ulcer Treatment Market Segment Insights
Therapy devices segment is expected to expand at a rapid pace
Based on treatments, the diabetic foot ulcer treatment market is divided into biologics, wound care, therapy devices, antibiotic medications, others. The biologics segment is expected to hold a key share of the market in the coming years. The biologics segment is subdivided into growth factors and skin grafts. The wound care segment is further subdivided into alginate dressings, hydrofiber dressings, foam dressings, film dressing, hydrocolloid dressings, surgical dressings, and hydrogel dressings.
On the other hand, the therapy devices segment is anticipated to expand at a rapid pace during the forecast period due to increasing adoption of medical devices for effectiveness, safer treatment of patients, and better targeted method. The therapy devices segment is subdivided into negative pressure wound therapy and ultrasound therapy.
Neuro-ischemic ulcers segment is projected to account for a major market share
On the basis of ulcer types, the diabetic foot ulcer treatment market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. Neuro-ischemic ulcers segment is most common type of ulcer. The neuro-ischemic ulcers segment is expected to account for a key share of the market during the forecast period. As per study conducted in 1980s, neuropathy is a major factor responsible for the cause of diabetic foot ulcer. In last two decades number of neuro-ischemic or ischemic ulceration cases are rising.
North America is expected to dominate the market
On the basis of regions, the diabetic foot ulcer treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to adequate healthcare facilities and increasing number of diabetic patients.
Because of capital-intensive nature, approval cycle and long R&D is needed in North America, which restraint the regional market growth. Still, growing adoption of new biologics and wound care devices for ulcers treatment are expected to drive regional growth. However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to growing prevalence of diabetes and huge geriatric population base in both China and India. This is also responsible for favorable legislation and rising adoption in developed countries such as Japan and Australia.
The global diabetic foot ulcer treatment market has been segmented on the basis of
- Growth Factors
- Skin Grafts
- Wound Care Dressings
- Alginate Dressings
- Hydrofiber Dressings
- Foam Dressings
- Film Dressing
- Hydrocolloid Dressings
- Surgical Dressings
- Hydrogel Dressings
- Therapy Devices
- Negative Pressure Wound Therapy
- Ultrasound Therapy
- Antibiotic Medications
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- ConvaTec, Inc.
- Acelity L.P. Inc.
- 3M Healthcare
- Coloplast A/S
- Smith & Nephew Plc.
- B. Braun Melsungen AG
- Medline Industries, Inc.
- Medtronic Plc.
- Organogenesis, Inc.
- Molnlycke Health Care AB
- BSN Medical GMBH
Key players competing in the diabetic foot ulcer treatment market are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH. Major market players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.